Related Experiment Video
Updated: May 20, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
Anti-inflammatory therapy in type 1 diabetes
Bernd Baumann1, Heba H Salem, Bernhard O Boehm
1Institute of Physiological Chemistry, Ulm University, Albert Einstein Allee 11, 89081, Ulm, Germany. bernd.baumann@uni-ulm.de
Current Diabetes Reports
|July 14, 2012
Summary
Type 1 diabetes (T1D) involves autoimmune destruction of insulin-producing beta-cells, driven by inflammation. This review explores anti-inflammatory strategies for T1D, examining their mechanisms and potential to halt disease progression.
Area of Science:
- Immunology
- Endocrinology
- Autoimmune Diseases
Background:
- Type 1 diabetes (T1D) is an autoimmune disorder characterized by the progressive loss of insulin-producing beta-cells in pancreatic islets.
- Immune cell infiltration (insulitis) and aberrant inflammatory processes, involving cytokines like IL-1β, TNFα, and INFγ, are central to beta-cell destruction.
- The role of inflammation in T1D pathogenesis is debated, ranging from a bystander effect to an active driver of beta-cell death.
Purpose of the Study:
- To review recent advancements in anti-inflammatory interventions for Type 1 diabetes.
- To discuss the mechanisms of action for these anti-inflammatory therapies.
- To evaluate the potential of these interventions to interfere with T1D development.
Main Methods:
- Review of preclinical studies and T1D animal models.
- Analysis of anti-inflammatory intervention strategies.
- Examination of immune cell involvement and cytokine signaling pathways.
Main Results:
- Various anti-inflammatory interventions show promise in T1D models.
- Understanding the interplay between innate and adaptive immunity is crucial.
- Targeting specific inflammatory pathways may prevent or delay beta-cell destruction.
Conclusions:
- Anti-inflammatory approaches represent a potential therapeutic avenue for Type 1 diabetes.
- Further research is needed to translate preclinical findings into clinical applications.
- Modulating the inflammatory environment in pancreatic islets could preserve beta-cell function.
More Related Videos
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...